GlassScriptPhysician profile
Philip Otterbeck
NPI 1831386424
$575,322.45
in general payments reported to CMS, 2019-2025
74 companies · $91K in 2025
The $91K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $52K · 2021: $65K · 2022: $119K · 2023: $59K · 2024: $76K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Food and Beverage: $20K · Travel and Lodging: $16K · Honoraria: $10K · Consulting Fee: $2,663 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,156.75 |
| Food and Beverage | $19,834.12 |
| Travel and Lodging | $15,974.88 |
| Honoraria | $10,000.00 |
| Consulting Fee | $2,662.50 |
| Education | $179.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $202,325.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $156,076.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $96,322.08 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $30,553.79 | 2022-2025 | |
| Esperion Therapeutics, INC. | $19,793.13 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $17,389.32 | 2019-2023 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,251.85 | 2019-2025 | Jardiance, Synjardy |
| Intra-Sana Laboratories | $10,605.33 | 2023-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $5,495.87 | 2019-2020 | |
| Corcept Therapeutics | $3,793.08 | 2019-2025 | Korlym |
| Vistapharm, INC. | $2,298.14 | 2021 | |
| Amgen INC. | $2,233.43 | 2019-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $1,768.88 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Amneal Pharmaceuticals LLC | $1,527.90 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $1,228.59 | 2019-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,110.80 | 2019-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Insulet Corporation | $1,058.43 | 2019-2025 | Omnipod |
| Abbvie INC. | $1,025.86 | 2019-2025 | |
| Amarin Pharma, INC. | $1,019.38 | 2019-2022 | |
| Abbott Laboratories | $839.21 | 2020-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $674.63 | 2025 | Yorvipath |
| Pfizer INC. | $631.04 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $543.58 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $500.99 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Grt US Holding, INC. | $424.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.01 | 2019-2024 | Cycloset |
| Novartis Pharmaceuticals Corporation | $370.45 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $329.87 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $301.83 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $249.73 | 2020-2025 | Contrave, Nexletol |
| Neurocrine Biosciences, INC. | $207.14 | 2021-2025 | |
| Mannkind Corporation | $177.05 | 2020-2022 | |
| Ibsa Pharma INC. | $175.62 | 2019-2025 | Tirosint, Licart, Tirosint |
| Ipsen Biopharmaceuticals, INC | $164.66 | 2019-2022 | |
| Eisai INC. | $161.38 | 2019 | |
| Recordati_rare_diseases_inc. | $160.70 | 2023-2025 | Isturisa, Signifor Lar, Enjaymo |
| Amphastar Pharmaceuticals, INC. | $130.36 | 2023-2025 | Baqsimi |
| Beta Bionics, INC. | $128.30 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Valeritas, INC. | $125.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $119.58 | 2019 | |
| Amryt Pharma Holdings LTD | $110.58 | 2023 | Mycapssa |
| Radius Health, INC. | $104.24 | 2021-2022 | |
| Lifescan, INC. | $103.88 | 2019-2022 | |
| Cequr Corporation | $102.57 | 2024-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $93.77 | 2020-2023 | Tepezza |
| Averitas Pharma INC. | $90.48 | 2024-2025 | Qutenza |
| Shire North American Group INC | $90.36 | 2019 | |
| Astellas Pharma US INC | $88.31 | 2023-2024 | Veozah |
| Madrigal Pharmaceuticals | $70.83 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $53.45 | 2024-2025 | Mycapssa |
| Regeneron Healthcare Solutions, INC. | $53.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $52.66 | 2024-2025 | Strensiq |
| Kyowa Kirin, INC. | $48.91 | 2023 | Crysvita |
| Acella Pharmaceuticals, LLC | $45.92 | 2024-2025 | NP Thyroid 60 |
| Embecta Corp. | $42.73 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $42.32 | 2025 | Twiist |
| Zealand Pharma US, INC. | $40.29 | 2021 | |
| Antares Pharma, INC. | $36.94 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $35.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $34.72 | 2020-2022 | |
| Echosens North America, INC. | $33.35 | 2019-2024 | Fibroscan |
| Becton, Dickinson and Company | $29.59 | 2019 | |
| Almatica Pharma LLC | $29.24 | 2025 | Teriparatide |
| Ionis Pharmaceuticals, INC. | $24.70 | 2025 | Tryngolza |
| Acerus Pharmaceuticals Corporation | $24.39 | 2020 | |
| Clarus Therapeutics INC. | $23.90 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $23.32 | 2025 | Imcivree |
| Soleno Therapeutics, INC. | $19.29 | 2025 | Vykat Xr |
| Globus Medical, INC. | $18.84 | 2025 | Senza |
| Glaxosmithkline, LLC. | $16.38 | 2025 | Shingrix |
| Azurity Pharmaceuticals, INC. | $15.89 | 2023 | Adthyza |
| Melinta Therapeutics, LLC | $14.05 | 2024 | Rezzayo, Vabomere, Orbactiv |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Otterbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.